Holland JF - Search Results

1

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.

Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF 3rd, Benisovich V, Navada S, Akahoho E, Wilck E, Taft DR, Roboz J, Wilhelm F, Holland JF. Ohnuma T, et al. Among authors: holland jf. Am J Cancer Res. 2013 Jun 20;3(3):323-38. Print 2013. Am J Cancer Res. 2013. PMID: 23841031 Free PMC article.

2

Discontinuous drug binding to proteins: binding of an antineoplastic benzyl styryl sulfone to albumin and enzymes in vitro and in phase I clinical trials.

Cho SY, Ohnuma T, Silverman LR, Holland JF, Roboz J. Cho SY, et al. Among authors: holland jf. Drug Metab Dispos. 2010 Sep;38(9):1480-5. doi: 10.1124/dmd.110.033001. Epub 2010 May 25. Drug Metab Dispos. 2010. PMID: 20501913

3

Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.

Oussenko IA, Holland JF, Reddy EP, Ohnuma T. Oussenko IA, et al. Among authors: holland jf. Cancer Res. 2011 Jul 15;71(14):4968-76. doi: 10.1158/0008-5472.CAN-10-1603. Epub 2011 Jun 6. Cancer Res. 2011. PMID: 21646468

4

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.

Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, Maniar M, Wilhelm F. Silverman LR, et al. Among authors: holland jf. Hematol Oncol. 2015 Jun;33(2):57-66. doi: 10.1002/hon.2137. Epub 2014 Apr 29. Hematol Oncol. 2015. PMID: 24777753 Free article.

5

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.

Navada SC, Fruchtman SM, Odchimar-Reissig R, Demakos EP, Petrone ME, Zbyszewski PS, Holland JF, Silverman LR. Navada SC, et al. Among authors: holland jf. Leuk Res. 2018 Jan;64:10-16. doi: 10.1016/j.leukres.2017.11.006. Epub 2017 Nov 11. Leuk Res. 2018. PMID: 29144985 Clinical Trial.

6

Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate.

Schwartz GK, Arkin H, Holland JF, Ohnuma T. Schwartz GK, et al. Among authors: holland jf. Cancer Res. 1991 Jan 1;51(1):55-61. Cancer Res. 1991. PMID: 1824824

7

Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture.

Kano Y, Ohnuma T, Okano T, Holland JF. Kano Y, et al. Among authors: holland jf. Cancer Res. 1988 Jan 15;48(2):351-6. Cancer Res. 1988. PMID: 3422052

8

Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme.

Kobayashi H, Dorai T, Holland JF, Ohnuma T. Kobayashi H, et al. Among authors: holland jf. Cancer Res. 1994 Mar 1;54(5):1271-5. Cancer Res. 1994. PMID: 8118816

9

Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide.

Roboz J, Jiang J, Holland JF, Bekesi JG. Roboz J, et al. Among authors: holland jf. Cancer Res. 1997 Nov 1;57(21):4795-802. Cancer Res. 1997. PMID: 9354441

10

Inhibition of microtubule assembly in tumor cells by 3-bromoacetylamino benzoylurea, a new cancericidal compound.

Jiang JD, Wang Y, Roboz J, Strauchen J, Holland JF, Bekesi JG. Jiang JD, et al. Among authors: holland jf. Cancer Res. 1998 May 15;58(10):2126-33. Cancer Res. 1998. PMID: 9605756

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

620 results

Search Page

Filters